Skeletal adverse effects with aromatase inhibitors in early breast cancer: evidence to date and clinical guidance
about
Aromatase inhibitors induced autoimmune disorders in patients with breast cancer: A review.Management of Aromatase Inhibitor-Associated Bone Loss (AIBL) in postmenopausal women with hormone sensitive breast cancer: Joint position statement of the IOF, CABS, ECTS, IEG, ESCEO IMS, and SIOGPharmacogenetics and aromatase inhibitor induced side effects in breast cancer patients.Molecular basis of aromatase inhibitor associated arthralgia: known and potential candidate genes and associated biomarkers.
P2860
Skeletal adverse effects with aromatase inhibitors in early breast cancer: evidence to date and clinical guidance
description
2015 nî lūn-bûn
@nan
2015 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2015 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
name
Skeletal adverse effects with ...... to date and clinical guidance
@ast
Skeletal adverse effects with ...... to date and clinical guidance
@en
Skeletal adverse effects with ...... to date and clinical guidance
@nl
type
label
Skeletal adverse effects with ...... to date and clinical guidance
@ast
Skeletal adverse effects with ...... to date and clinical guidance
@en
Skeletal adverse effects with ...... to date and clinical guidance
@nl
prefLabel
Skeletal adverse effects with ...... to date and clinical guidance
@ast
Skeletal adverse effects with ...... to date and clinical guidance
@en
Skeletal adverse effects with ...... to date and clinical guidance
@nl
P2093
P2860
P50
P356
P1476
Skeletal adverse effects with ...... to date and clinical guidance
@en
P2093
Ignasi Tusquets
Laia Garrigos
Maria Rodriguez Sanz
Sonia Servitja
Tamara Martos
P2860
P304
P356
10.1177/1758834015598536
P407
P577
2015-09-01T00:00:00Z